• F Xu, L Xu, M Wang, G An, and G Feng.
• Department of General Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
• Colorectal Dis. 2015 May 1;17(5):O100-7.

AimThe accuracy and clinical value of circulating microRNA-21 (miR-21) were assessed as a novel diagnostic biomarker of colorectal cancer (CRC).MethodMedline/PubMed, EMBASE, the Cochrane Library databases and grey literature (Google scholar; British Library) were searched up to 29 September 2014 for eligible studies of the association between blood-based miR-21 and a diagnosis of CRC. Quality Assessment of Diagnostic Accuracy Studies (QUADAS) was employed to assess the quality of the included studies by two investigators. Stata12.0 and Meta-DiSc1.4 software were applied to test the heterogeneity using Cochran's Q test and I(2) statistics and to perform the meta-analysis.ResultsSeven studies with 676 CRC patients and 417 controls were included in the meta-analysis. All were of high quality (QUADAS scores 12 or 13). For miR-21, the pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and diagnostic odds ratio to predict CRC were 75% [95% confidence interval (CI) 63-83%], 84% (95% CI 79-87%), 4.61 (95% CI 3.38-6.29), 0.30 (95% CI 0.20-0.46) and 16.89 (95% CI 7.56-37.73) after using a random-effects model analysis. The area under the summary receiver operating characteristic curve was 0.86 (95% CI 0.83-0.89).ConclusionThe results suggest that circulating miR-21 is a biomarker with moderate sensitivity and specificity for CRC.Colorectal Disease © 2015 The Association of Coloproctology of Great Britain and Ireland.

16 keywords...

hide…